NYSE · PHARMACEUTICAL PREPARATIONS · LARGE CAP
Perrigo Company PLC PRGO
14 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY9 YEARS OF DIVIDEND GROWTH
Revenue · FY2025
$4.3B
▼ 2.8% vs FY2024
Dividend streak
9 yrs
Raised every year since 2017
EPS · FY25
$-10.29
Dividend / sh · FY25
$1.16
Payout · FY25
-11%
ROE · FY25
-39.3%
Net margin · FY25
-33.5%
Dividend coverage
-8.9×
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 4.3B
Revenue, FY2025 · full 14-year series below
Revenue
Net income
The company lost 34 cents on every revenue dollar this year.
Per share
USD -10.29
Diluted EPS, FY2025
EPS
Dividend
The dividend was paid in a year without profit.
Profitability
-39.3%
Return on equity, FY2025
ROE
Operating margin-26.4%
Net margin-33.5%
Return on assets-15.7%
Each USD of equity lost 39 cents this year.
Returned to shareholders
USD 159.3M
returned in FY2025 · dividends + net buybacks
Dividends paidUSD 159.3M
Net buybacks—
Share of profit-11.2%
Consecutive raises9 years
USD 159.3M in dividends went back to shareholders in a year without profit.
Growth
+0.8% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−1.5%
+0.8%
Dividend / share
+3.7%
+5.2%
Returned to shareholders
+3.8%
−11.2%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.14B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 8.5B
total assets, end of FY2025
Total assetsUSD 8.5B
EquityUSD 2.9B
CashUSD 531.6M
Gross debtUSD 3.6B
Net debtUSD 3.1B
Current ratio2.76×
Net debt stands at 106% of equity.
History
14 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2014
2013
2012
2011
Revenue $B
4.3
4.4
4.7
4.5
4.1
4.1
3.9
4.7
4.9
5.3
4.2
3.9
3.5
3.2
Operating income $B
−1.1
0.1
0.2
0.1
0.4
0.3
0.2
0.2
0.6
−2.0
0.7
0.6
0.7
0.6
EBITDA $B
−0.8
0.4
0.5
0.4
0.7
0.7
0.6
0.7
1.0
−1.5
0.9
0.8
0.8
0.7
Income tax $B
0.1
0.1
−0.0
−0.0
0.4
−0.0
−0.0
0.2
0.2
−0.8
0.1
0.1
0.2
0.1
Net income $B
−1.4
−0.2
−0.0
−0.1
−0.1
−0.2
0.1
0.1
0.1
−4.0
0.1
0.2
0.4
0.4
EPS, diluted $
−10.29
−1.25
−0.09
−1.04
−0.52
−1.19
1.07
0.95
0.84
−28.01
0.97
2.01
4.68
4.27
Dividend / sh $
1.16
1.10
1.09
1.04
0.96
0.90
0.82
0.76
0.64
0.58
0.46
0.39
0.35
0.31
Payout %
−11
−89
−1179
−101
−188
−76
77
80
76
−2
48
20
7
7
ROE %
−39.3
−3.8
−0.3
−2.8
−1.3
−2.8
2.5
2.2
2.0
−50.0
1.4
4.2
21.1
21.7
Shares out B
0.14
0.14
0.14
0.13
·
·
·
·
·
·
·
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
56 of 56
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed